- Home
- SLMBP vs IOVA Comparison
SLMBP vs IOVA Comparison
Compare SLMBP & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SLMBP | IOVA |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | 1788 | 975 |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 1.5B |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | SLMBP | IOVA |
|---|---|---|
| Price | $75.02 | $3.64 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 2.3K | ★ 13.0M |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.84 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $51.55 |
| Revenue Next Year | N/A | $37.55 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $69.29 | $1.64 |
| 52 Week High | $83.15 | $5.63 |
Technical Indicators
Market Signals| Indicator | SLMBP | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 49.13 | 49.76 |
| Support Level | $74.07 | $2.02 |
| Resistance Level | $75.99 | $4.34 |
| Average True Range (ATR) | 0.95 | 0.31 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 84.86 | 38.40 |
Price Performance
Historical ComparisonAbout SLMBP SLM Corporation Floating Rate Non-Cumulative Preferred Stock Series B
SLM Corp is an education solutions company. Its business is to originate and service loans to students and their families to finance the cost of their education. The term' Private Education Loans to mean education loans to students or their families that are not made, insured, or guaranteed by any state or federal government.
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.